메뉴 건너뛰기




Volumn 17, Issue 5, 2016, Pages 612-621

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: An international, randomised, open-label, phase 3 trial

(26)  Lipton, Jeffrey H a   Chuah, Charles b   Guerci Bresler, Agnès c   Rosti, Gianantonio d   Simpson, David e   Assouline, Sarit f   Etienne, Gabriel g   Nicolini, Franck E h   Le Coutre, Philipp i   Clark, Richard E j   Stenke, Leif k   Andorsky, David l   Oehler, Vivian m   Lustgarten, Stephanie n   Rivera, Victor M n   Clackson, Timothy n   Haluska, Frank G n   Baccarani, Michele d   Cortes, Jorge E o   Guilhot, François p   more..


Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; ASPARTATE AMINOTRANSFERASE; IMATINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

EID: 84964318463     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)00080-2     Document Type: Article
Times cited : (223)

References (29)
  • 1
    • 10744233716 scopus 로고    scopus 로고
    • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    • O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
    • (2003) N Engl J Med , vol.348 , pp. 994-1004
    • O'Brien, S.G.1    Guilhot, F.2    Larson, R.A.3
  • 2
    • 80055070888 scopus 로고    scopus 로고
    • Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
    • Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011, 118:4567-4576.
    • (2011) Blood , vol.118 , pp. 4567-4576
    • Cortes, J.E.1    Kantarjian, H.M.2    Brümmendorf, T.H.3
  • 3
    • 84899072118 scopus 로고    scopus 로고
    • Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
    • Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 2014, 123:2317-2324.
    • (2014) Blood , vol.123 , pp. 2317-2324
    • Shah, N.P.1    Guilhot, F.2    Cortes, J.E.3
  • 4
    • 36348968931 scopus 로고    scopus 로고
    • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    • Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
    • (2007) Blood , vol.110 , pp. 3540-3546
    • Kantarjian, H.M.1    Giles, F.2    Gattermann, N.3
  • 5
    • 49249121723 scopus 로고    scopus 로고
    • Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
    • Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008, 26:3204-3212.
    • (2008) J Clin Oncol , vol.26 , pp. 3204-3212
    • Shah, N.P.1    Kantarjian, H.M.2    Kim, D.W.3
  • 6
    • 79251546724 scopus 로고    scopus 로고
    • Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
    • Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117:1141-1145.
    • (2011) Blood , vol.117 , pp. 1141-1145
    • Kantarjian, H.M.1    Giles, F.J.2    Bhalla, K.N.3
  • 7
    • 84887127701 scopus 로고    scopus 로고
    • A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
    • Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013, 369:1783-1796.
    • (2013) N Engl J Med , vol.369 , pp. 1783-1796
    • Cortes, J.E.1    Kim, D.W.2    Pinilla-Ibarz, J.3
  • 8
    • 84923643914 scopus 로고    scopus 로고
    • Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial
    • (abstract).
    • Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 2014, 124:3135. (abstract).
    • (2014) Blood , vol.124 , pp. 3135
    • Cortes, J.E.1    Kim, D.W.2    Pinilla-Ibarz, J.3
  • 9
    • 84893527395 scopus 로고    scopus 로고
    • Impact of baseline (BL) mutations, including low-level and compound mutations, on ponatinib response and end of treatment (EOT) mutation analysis in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML)
    • (abstract).
    • Deininger MW, Shah NP, Cortes JE, et al. Impact of baseline (BL) mutations, including low-level and compound mutations, on ponatinib response and end of treatment (EOT) mutation analysis in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML). Blood 2013, 122:652. (abstract).
    • (2013) Blood , vol.122 , pp. 652
    • Deininger, M.W.1    Shah, N.P.2    Cortes, J.E.3
  • 10
    • 0021336851 scopus 로고
    • Prognostic discrimination in "good-risk" chronic granulocytic leukemia
    • Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984, 63:789-799.
    • (1984) Blood , vol.63 , pp. 789-799
    • Sokal, J.E.1    Cox, E.B.2    Baccarani, M.3
  • 11
    • 84881298446 scopus 로고    scopus 로고
    • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
    • Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122:872-884.
    • (2013) Blood , vol.122 , pp. 872-884
    • Baccarani, M.1    Deininger, M.W.2    Rosti, G.3
  • 12
    • 84865864744 scopus 로고    scopus 로고
    • Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
    • Hanfstein B, Müller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012, 26:2096-2102.
    • (2012) Leukemia , vol.26 , pp. 2096-2102
    • Hanfstein, B.1    Müller, M.C.2    Hehlmann, R.3
  • 13
    • 84862907694 scopus 로고    scopus 로고
    • Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
    • Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012, 30:232-238.
    • (2012) J Clin Oncol , vol.30 , pp. 232-238
    • Marin, D.1    Ibrahim, A.R.2    Lucas, C.3
  • 14
    • 77953691179 scopus 로고    scopus 로고
    • Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
    • Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
    • (2010) N Engl J Med , vol.362 , pp. 2251-2259
    • Saglio, G.1    Kim, D.W.2    Issaragrisil, S.3
  • 15
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    • Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3
  • 16
    • 84866175467 scopus 로고    scopus 로고
    • Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial
    • Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012, 30:3486-3492.
    • (2012) J Clin Oncol , vol.30 , pp. 3486-3492
    • Cortes, J.E.1    Kim, D.W.2    Kantarjian, H.M.3
  • 17
    • 77958595179 scopus 로고    scopus 로고
    • Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
    • Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010, 116:3758-3765.
    • (2010) Blood , vol.116 , pp. 3758-3765
    • Hughes, T.P.1    Hochhaus, A.2    Branford, S.3
  • 18
    • 84893136765 scopus 로고    scopus 로고
    • Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
    • Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014, 123:494-500.
    • (2014) Blood , vol.123 , pp. 494-500
    • Jabbour, E.1    Kantarjian, H.M.2    Saglio, G.3
  • 19
    • 84897007532 scopus 로고    scopus 로고
    • Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
    • Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014, 123:1353-1360.
    • (2014) Blood , vol.123 , pp. 1353-1360
    • Hughes, T.P.1    Saglio, G.2    Kantarjian, H.M.3
  • 21
    • 84874000814 scopus 로고    scopus 로고
    • BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib
    • Kim DD, Lee H, Kamel-Reid S, Lipton JH BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. Br J Haematol 2013, 160:630-639.
    • (2013) Br J Haematol , vol.160 , pp. 630-639
    • Kim, D.D.1    Lee, H.2    Kamel-Reid, S.3    Lipton, J.H.4
  • 22
    • 84946832907 scopus 로고    scopus 로고
    • East Hanover, NJ, (accessed April 5, 2016).
    • Tasigna [package insert] 2015, Novartis Pharmaceuticals Corporation, East Hanover, NJ, (accessed April 5, 2016). https://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf.
    • (2015) Tasigna [package insert]
  • 23
    • 84923682203 scopus 로고    scopus 로고
    • Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients
    • Knickerbocker R, Dorer DJ, Haluska FG, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Blood 2014, 124:4546.
    • (2014) Blood , vol.124 , pp. 4546
    • Knickerbocker, R.1    Dorer, D.J.2    Haluska, F.G.3
  • 24
    • 84923682210 scopus 로고    scopus 로고
    • Ponatinib efficacy and safety in patients with the T315I mutation: long-term follow-up of phase 1 and phase 2 (PACE) trials
    • (abstract).
    • Mauro MJ, Cortes JE, Hochhaus A, et al. Ponatinib efficacy and safety in patients with the T315I mutation: long-term follow-up of phase 1 and phase 2 (PACE) trials. Blood 2014, 124:4552. (abstract).
    • (2014) Blood , vol.124 , pp. 4552
    • Mauro, M.J.1    Cortes, J.E.2    Hochhaus, A.3
  • 25
    • 84893181293 scopus 로고    scopus 로고
    • Abl family kinases regulate endothelial barrier function in vitro and in mice
    • Chislock EM, Pendergast AM Abl family kinases regulate endothelial barrier function in vitro and in mice. PLoS One 2013, 8:e85231.
    • (2013) PLoS One , vol.8 , pp. e85231
    • Chislock, E.M.1    Pendergast, A.M.2
  • 26
    • 84880692698 scopus 로고    scopus 로고
    • Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival
    • Chislock EM, Ring C, Pendergast AM Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci USA 2013, 110:12432-12437.
    • (2013) Proc Natl Acad Sci USA , vol.110 , pp. 12432-12437
    • Chislock, E.M.1    Ring, C.2    Pendergast, A.M.3
  • 27
    • 84897573995 scopus 로고    scopus 로고
    • Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
    • Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014, 32:424-430.
    • (2014) J Clin Oncol , vol.32 , pp. 424-430
    • Rousselot, P.1    Charbonnier, A.2    Cony-Makhoul, P.3
  • 28
    • 84879710913 scopus 로고    scopus 로고
    • Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    • Hochhaus A, Saglio G, Larson RA, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013, 121:3703-3708.
    • (2013) Blood , vol.121 , pp. 3703-3708
    • Hochhaus, A.1    Saglio, G.2    Larson, R.A.3
  • 29
    • 84940797444 scopus 로고    scopus 로고
    • BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
    • Hughes TP, Saglio G, Quintás-Cardama A, et al. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia 2015, 29:1832-1838.
    • (2015) Leukemia , vol.29 , pp. 1832-1838
    • Hughes, T.P.1    Saglio, G.2    Quintás-Cardama, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.